Veracyte says Decipher predicts abiraterone benefit in very high-risk prostate cancer
Veracyte announced new results from a retrospective Phase III STAMPEDE analysis showing its Decipher test can identify very high-risk, nonmetastatic prostate cancer patients more likely to benefit from adding abiraterone to ADT. At five years, distant-metastasis reduction was 10% for patients with high scores and 11% for those with very high scores, versus 2% for lower scores. The findings will be presented at ESMO on October 24, 2026.
Why it matters
The result could help doctors weigh abiraterone's potential benefit against its added side effects and treatment burden for patients with very high-risk disease. Veracyte said the findings strengthen the rationale for using Decipher before treatment-intensification decisions and could support broader adoption of the test.
Key facts
- 1The STAMPEDE analysis covered 401 patients who received ADT alone or ADT with abiraterone. stocktitan.net
- 2At five years, adding abiraterone reduced distant-metastasis events by 10% for patients with high Decipher scores, 11% for those with very high scores and 2% for those with lower scores. stocktitan.net
- 3The treatment-by-Decipher interaction for distant metastasis was statistically significant among node-negative patients, with p=0.01. stocktitan.net
- 4A separate real-world analysis included data from over 27,000 patients but was designed to assess Decipher's prognostic value rather than predict abiraterone benefit. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.